Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies
Status:
Completed
Trial end date:
2020-07-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine wether pirfenidone is safe and effective in the
treatment of pulmonary fibrosis with anti-myeloperoxydase (MPO) antibodies or pulmonary
fibrosis with anti-MPO associated vasculitis.